Abstract 165P
Background
Lenvatinib is a new first-line molecular target drug for hepatocellular carcinoma (HCC) that is available worldwide. We evaluated the efficacy and safety of lenvatinib for unresectable HCC.
Methods
This study population included thirty-seven patients that we could follow from 42 patients who received lenvatinib between April 2018 and May 2019 in our hospital. We evaluated the lenvatinib treatment profile, the clinical response (according to mRECIST), adverse events (according to CTCAE v.4.0), progression free survival (PFS), overall survival (OS), conversion therapy and the tumor response after progressive disease (PD) and serious adverse events (sAEs).
Results
The study population included 34 male patients (91.9%). Eleven patients were positive for HBV, 14 were positive for HCV, 6 had a history of alcohol intake. The Child Pugh scores (CPS) were as follows: 5 (n = 27), 6 (n = 7), 7(n = 3). Fifteen patients had BCLC stage B and 22 had C. The reasons for lenvatinib included TACE failure/refractoriness (35.3%), vascular invasion (32%), extrahepatic spread: (27.0%), PD after other molecular target therapies (16.2%) . The initial dose was 12 mg (90%) in patients with a body weight of > 60 kg, 8 mg (68.8%) in patients with a body weight of < 60 kg; in these two groups, 50.0% and 66.6% of patients received a half-dose reduction after one month. The tumor responses were classified as follows: objective response rate (ORR), 35.1%; disease control rate (DCR), 70.3%; PFS, 7.3 months (95% CI 4.9-11.2); OS, the median OS was not reached. There was no significant differences in the CPS between before and after therapy (p = 0.68). The rates of AEs (any grade/grade ≥3) were as follows: hypertension (37.8/0%), protein urea (29.7/13.5%), hypothyroidism (16.2/0%), fatigue (8.1/2.7%), hand-foot skin reaction (5.4/0%), hepatic encephalopathy (8.1%), respectively. The ORR and DCR of the grade ≥3 and grade <2 groups did not differ to a statistically significant extent. In the grade ≥3 group, 4 patients obtained a clinical benefit, however could not receive chemotherapies because of a poor performance status (≥3).
Conclusions
Lenvatinib is good therapeutic drug for advanced HCC, however it is very important to pay attention to sAEs in patients who show a clinical benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO31 - Primary pulmonary sarcoma
Presenter: Khilola Ubaydullaeva
Session: Poster display session
Resources:
Abstract
YO32 - prostatic rhabdomyosarcoma in an adult patient: A case study
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
YO33 - Hyponatremia – slaying the dragon or chasing a mirage- a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO34 - A rare endocrinological syndrome presenting with weakness in Soft tissue sarcoma - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO35 - Gefitinib induced movement disorder - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO36 - A case of BRAF V600E mutated non-small-cell lung cancer with pleomorphic features
Presenter: Reiko Matsuzawa
Session: Poster display session
Resources:
Abstract
YO37 - Intraventricular metastasis as the first presentation of non-small cell lung cancer
Presenter: Siraphong Putraveephong
Session: Poster display session
Resources:
Abstract
YO38 - Cerebral metastases from a thymic malignancy: a case report
Presenter: Marfu'au Nik Eezamuddeen
Session: Poster display session
Resources:
Abstract
YO39 - Primary Follicular Thyroid Carcinoma Metastatic to the Kidney Mimicking Renal Cell Carcinoma: A Case Report
Presenter: Jestoni Aranilla
Session: Poster display session
Resources:
Abstract
YO40 - A Rare Case of Primary Malignant Giant Cell Tumor of Tibia
Presenter: Gowthami Venugopal
Session: Poster display session
Resources:
Abstract